Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck & Co., has revealed its plans to roll out Tredaptive (ER niacin/laropiprant) in Mexico, Germany and the UK, by the third quarter of the year. Tredaptive, also called as Cordaptive, is a lipid-modifying therapy for patients with primary hypercholesterolemia and mixed dyslipidemia.
Subscribe to our email newsletter
Luciano Rossetti of Merck Research Laboratories, said: “Merck is pleased that we are now able to supply Tredaptive in approved markets and continue our long-standing commitment to help address unmet medical needs in cardiovascular care.”
Incorporated in 1891, Merck is engaged in discovery, development, production and marketing of medicines and vaccines. The company has operations in various countries and Tredaptive is approved in 39 nations, excluding the US.